title: [Changes and clinical significance of serum soluble Apo-1/Fas in pancreatic cancer].
abstract: OBJECTIVE
  To detect changes of serum soluble Apo-1/Fas (sApo-1/Fas) in pancreatic cancer patients and to investigate its clinical value in assessing the effect of chemotherapy.
  
  
  METHODS
  The serum level of sApo-1/Fas in 30 normal control subjects and 58 pancreatic cancer patients were detected using enzyme-linked immunosorbent assay (ELISA), and the sApo-1/Fas level of 48 pancreatic cancer patients, before and after chemotherapy was compared.
  
  
  RESULTS
  Compared with the level of the control group, the level of serum soluble Apo-1/Fas was significantly correlated with clinical stage but not with age, sex or pathologic type of pancreatic cancer. It was elevated gradually from stage II to IV (P < 0.01). However, it would obviously decrease in pancreatic cancer patients after chemotherapy (P < 0.01).
  
  
  CONCLUSIONS
  The serum soluble Apo-1/Fas may be involved in the development of pancreatic cancer, and it may be used as one parameter to assess the disease status and prognosis of pancreatic cancer patient.
authors.affiliation: Department of Medical Oncology, Hospital of Guangdong Medical College, Zhanjiang 524001, China. lianqilian@gdmc.edu.cn
authors.forename: Qi-lian
authors.initials: QL
authors.lastname: Liang
authors.forename: Da-chao
authors.initials: DC
authors.lastname: Pan
authors.forename: Zheng-min
authors.initials: ZM
authors.lastname: Yin
authors.forename: Guo-xun
authors.initials: GX
authors.lastname: Liu
authors.forename: Qin
authors.initials: Q
authors.lastname: Yang
authors.forename: Jie-rong
authors.initials: JR
authors.lastname: Xie
authors.forename: You-wen
authors.initials: YW
authors.lastname: Fu
authors.forename: Liang-zhen
authors.initials: LZ
authors.lastname: Cai
mesh_terms: D002288:Adenocarcinoma, Mucinous / Q000097:blood / Q000188:drug therapy; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D021441:Carcinoma, Pancreatic Ductal / Q000097:blood / Q000188:drug therapy; D002945:Cisplatin / Q000008:administration & dosage; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D018450:Disease Progression; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010190:Pancreatic Neoplasms / Q000097:blood* / Q000188:drug therapy; D011379:Prognosis; D012074:Remission Induction; D019014:fas Receptor / Q000097:blood*; D000093542:Gemcitabine
chemical_list: D019014:fas Receptor; D003841:Deoxycytidine; D002945:Cisplatin; D000093542:Gemcitabine